The combined copeptin/cTN testing has the potential to save costs and staff time in acute
care and for the entire hospital stay. The primary explanations for these findings are early
identification and ruling out patients without AMI along with the associated reduced need for
acute medical treatment.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202133 >
The direct measurement of hypertonic saline–stimulated plasma copeptin had greater diagnostic accuracy than the water-deprivation test in patients with hypotonic polyuria.
https://www.nejm.org/doi/full/10.1056/NEJMoa1803760
High copeptin levels are associated with the development and the progression of CKD in the general population. Intervention studies are needed to assess the potential beneficial effect on kidney health in the general population of reducing vasopressin secretion or action.
https://doi.org/10.1172/jci.insight.121479 >
Copeptin (the C-terminal glycoprotein of the precursor AVP peptide) is an accurate surrogate marker of AVP release that is stable and easily measured by immunoassay. Cohort studies show that serum copeptin is correlated with disease severity in ADPKD, and predicts future renal events [decline in renal function and increase in total kidney volume (TKV)].
https://www.ncbi.nlm.nih.gov/pubmed/29527508 >
Among adults with chronic kidney disease, coaching to increase water intake compared with coaching to maintain the same water intake did not significantly slow the decline in kidney function after 1 year. However, the study may have been underpowered to detect a clinically important difference.
https://www.ncbi.nlm.nih.gov/pubmed/29801012 >